Roche Pipeline Already Genentech-Loaded
This article was originally published in The Pink Sheet Daily
Executive Summary
Candidates In Phase II And BeyondHow much of Genentech is in Roche's pipeline? Quite a bit. Of the 27 programs in Phase II development or later, one-third have their origins in Genentech's laboratories. Here's a summary of the crucial drugs and on-going clinical trials. (Source: Company websites)
|
Candidates In Phase II And Beyond How much of Genentech is in Roche's pipeline? Quite a bit. Of the 27 programs in Phase II development or later, one-third have their origins in Genentech's laboratories. Here's a summary of the crucial drugs and on-going clinical trials. (Source: Company websites) Product Indication Avastin VEGF inhibitor currently approved for use in lung cancer, renal cell cancer, colorectal, and metastatic breast cancer. Other potential indications include: first-line use for ovarian cancer (Phase III); pancreatic cancer (Phase III); prostate cancer (III); and glioblastoma (Phase III). Currently being studied worldwide in more than 450 clinical trials and in more than 30 different tumor types. Tarceva Studied for use in non small cell lung cancer as a first line therapy in conjunction with chemotherapy. Avastin/Tarceva In pivotal trials as a first line therapy for metastatic, non-squamous, non-small cell lung cancer. Herceptin/Avastin Combination of VEGF inhibitor + anti-Her2 antibody. Ongoing testing in Phase III trials as a first-line agent for Her-2 positive metastatic breast cancer. Rituxan Anti-CD20 antibody recruits the body's natural defenses to attack and malignant B-cells. Phase III clinical trials for relapsed chronic lymphocytic leukemia and follicular non-Hodgkin's lymphoma, are on-going. Rituxan/Avastin Anti-CD20/VEGF inhibitor combination in Phase III for use in aggressive Non-Hodgkin's Leukemia. Pertuzumab This humanized antibody is the first in a new class of agents known as HER dimerization inhibitors (HDI) that block the ability of the HER2 receptor to collaborate with other family members, triggering cell death. Phase III clinical trial evaluating pertuzumab in combination with Herceptin and chemotherapy for HER2-positive first-line metastatic breast cancer is on-going. Ocrelizumab Second generation anti-CD20 antibody. Molecule is currently in pivotal trials for rheumatoid arthritis and lupus nephritis; and a Phase II clinical trial is planned for relapsing remitting multiple sclerosis. R3502 New molecular entity. The molecule is a combination of the Herceptin monoclonal chemically linked to a highly potent antimicrotubule drug (DM1)derived from maytansine. Currently in Phase III for metastatic breast cancer. |